April 11, 2019
WELLESLEY, Mass., April 11, 2019–Improving technology and efforts to fight illicit drug use are helping to push the global drug testing market, according to the latest report by BCC Research, “Drugs of Abuse Testing: Technologies and Global Markets.”
The industry expects to see a compound annual growth rate (CAGR) of 5.6% through 2023, when it could be worth $4.6 billion, according to the report.
Major players in the market include Abbott Diagnostics (ABT), Agilent Technologies (A), Princeton BioMediTech, Roche Diagnostics (ROG) and Siemens Medical Solutions (SHL).
Research Highlights
“The overall demand for drug of abuse testing is rising,” notes the report’s authors. “DOA testing is used most heavily by healthcare service providers, public and private organizations and other government agencies. The two main technologies used for onsite screening testing and laboratory testing of drugs of abuse are immunoassay techniques and chromatography.”
Marijuana Legalization Not Expected to Slow Test Sales Through the Forecast Period
Legalized marijuana is now common in many parts of the United States as well as countries like Canada and Uruguay. Many workplaces, however, still require drug testing, and drug testing is federally mandated for millions of American workers such as commercial drivers, airline pilots, railroad engineers, and nuclear plant workers. While the legalization conflict between state and federal laws in the U.S. is likely to reach the U.S. Supreme Court, the market is unlikely to see significant change.
Editors/reporters requesting analyst interviews should contact Sarah Greenberg at press@bccresearch.com.
Drugs of Abuse Testing: Technologies and Global Markets( PHM013H )
Publish Date: Mar 2019
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.